Genome Wide Expression Analysis of the Effect of the Chinese Patent Medicine Zilongjin Tablet on Four Human Lung Carcinoma Cell Lines

Authors

  • Ping Zhang,

    1. Tianjin Zhongxin Pharmaceutical Group Co., Ltd, Tianjin, China
    Search for more papers by this author
  • Xin Wang,

    1. Tianjin Long Shun Rong Pharmaceutical Factory of Tianjin Zhongxin Pharmaceutical Group Co., Ltd, Tianjin, China
    Search for more papers by this author
  • Songjin Xiong,

    1. Tianjin Biochip Corporation, Tianjin, China
    Search for more papers by this author
  • Shaoping Wen,

    1. Tianjin Biochip Corporation, Tianjin, China
    Search for more papers by this author
  • Song Gao,

    1. Tianjin Long Shun Rong Pharmaceutical Factory of Tianjin Zhongxin Pharmaceutical Group Co., Ltd, Tianjin, China
    Search for more papers by this author
  • Lei Wang,

    1. TEDA School of Biological Sciences and Biotechnology, Nankai University, Tianjin, China
    2. Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
    3. Tianjin Research Center for Functional Genomics and Biochips, TEDA College, Nankai University, Tianjin, China
    4. Tianjin Key Laboratory of Microbial Functional Genomics, TEDA College, Nankai University, Tianjin, China
    Search for more papers by this author
  • Boyang Cao

    Corresponding author
    1. Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
    2. Tianjin Research Center for Functional Genomics and Biochips, TEDA College, Nankai University, Tianjin, China
    3. Tianjin Key Laboratory of Microbial Functional Genomics, TEDA College, Nankai University, Tianjin, China
    • TEDA School of Biological Sciences and Biotechnology, Nankai University, Tianjin, China
    Search for more papers by this author

Boyang Cao, TEDA School of Biological Sciencesand Biotechnology, Nankai University, 23# HongDa Street, TEDA, Tianjin 300457, China.

E-mail: boyangcao@nankai.edu.cn

Abstract

Zilongjin (ZLJ) tablet, which is a traditional Chinese medicine, has been approved as a new anti-tumor drug by the State Food and Drug Administration of China; however, its anti-cancer mechanisms remain elusive. The goal of this study was to investigate the underlying anti-cancer activities of ZLJ tablet in vitro. In this study, four lung cancer cell lines, A549, H446, H460 and H520, were treated with 2.2 mg/mL of ZLJ solution for 24 h at 37 °C under 5% CO2. RNA was isolated and a microarray experiment using the Affymetrix Human Genome U133 plus 2.0 Array was employed to differentiate the expression patterns of cancer-related genes after drug treatment. Of 483 genes in 63 functional categories and 25 different pathways that showed at least a 2-fold change of expression level in the four cancer cell lines, 170 genes were upregulated, and 313 genes were downregulated. Eleven of the 483 genes were cancer-related and belong to the three known pathways: apoptosis, cell cycle regulation and mitogen-activated protein kinase (MAPK) cascade. The microarray data were validated by real-time RT-PCR. The results of this investigation suggest possible anti-cancer mechanisms of the ZLJ tablet, and lay a foundation to further analyse its therapeutic roles. Copyright © 2011 John Wiley & Sons, Ltd.

Ancillary